139 related articles for article (PubMed ID: 11136569)
1. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
[TBL] [Abstract][Full Text] [Related]
3. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
[TBL] [Abstract][Full Text] [Related]
4. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
[TBL] [Abstract][Full Text] [Related]
5. Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation.
Bernstein AM; Twining SS; Warejcka DJ; Tall E; Masur SK
Mol Biol Cell; 2007 Jul; 18(7):2716-27. PubMed ID: 17507651
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Mahmood N; Mihalcioiu C; Rabbani SA
Front Oncol; 2018; 8():24. PubMed ID: 29484286
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.
Yatsenko T; Rios R; Nogueira T; Takahashi S; Tabe Y; Naito T; Takahashi K; Hattori K; Heissig B
Front Immunol; 2023; 14():1299792. PubMed ID: 38313435
[TBL] [Abstract][Full Text] [Related]
8. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
[TBL] [Abstract][Full Text] [Related]
9. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.
Fang H; Placencio VR; DeClerck YA
J Natl Cancer Inst; 2012 Oct; 104(19):1470-84. PubMed ID: 22984202
[TBL] [Abstract][Full Text] [Related]
10. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
[TBL] [Abstract][Full Text] [Related]
11. Changes in plasma soluble urokinase plasminogen activator receptor levels across pregnancy and in relation to hypertensive disorders.
Cowell W; Limaye M; Brukbaker SG; Silverstein JS; Mehta-Lee SS; Kahn LG; Malaga-Dieguez L; Reiser J; Trasande L
Am J Obstet Gynecol MFM; 2023 May; 5(5):100825. PubMed ID: 36775198
[No Abstract] [Full Text] [Related]
12. Role of adipocytokines in endometrial cancer progression.
Li R; Dong F; Zhang L; Ni X; Lin G
Front Pharmacol; 2022; 13():1090227. PubMed ID: 36578551
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Abbink K; Zusterzeel PLM; Geurts-Moespot A; van der Steen R; Span PN; Sweep FCGJ
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1725-1735. PubMed ID: 32394054
[TBL] [Abstract][Full Text] [Related]
14. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
Sereff SB; Daniels MW; Wittliff JL
J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.
Nakatsuka E; Sawada K; Nakamura K; Yoshimura A; Kinose Y; Kodama M; Hashimoto K; Mabuchi S; Makino H; Morii E; Yamaguchi Y; Yanase T; Itai A; Morishige KI; Kimura T
Oncotarget; 2017 Oct; 8(52):89887-89902. PubMed ID: 29163796
[TBL] [Abstract][Full Text] [Related]
16. AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.
Divine LM; Nguyen MR; Meller E; Desai RA; Arif B; Rankin EB; Bligard KH; Meyerson C; Hagemann IS; Massad M; Thaker PH; Hagemann AR; McCourt CK; Powell MA; Mutch DG; Fuh KC
Oncotarget; 2016 Nov; 7(47):77291-77305. PubMed ID: 27764792
[TBL] [Abstract][Full Text] [Related]
17. High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.
Thielemann A; Baszczuk A; Kopczyński P; Kopczyński Z
Contemp Oncol (Pozn); 2013; 17(5):440-5. PubMed ID: 24596533
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.
Memarzadeh S; Kozak KR; Chang L; Natarajan S; Shintaku P; Reddy ST; Farias-Eisner R
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10647-52. PubMed ID: 12130664
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]